Related Experiment Video
Updated: Dec 29, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress
Sona Hubackova1, Eliska Davidova2,3, Stepana Boukalova2
1Laboratory of Molecular Therapy, Institute of Biotechnology, Czech Academy of Sciences, Prague-West, 252 50, Czech Republic. sona.hubackova@ibt.cas.cz.
Abstract:
p53-mutated tumors often exhibit increased resistance to standard chemotherapy and enhanced metastatic potential. Here we demonstrate that inhibition of dihydroorotate dehydrogenase (DHODH), a key enzyme of the de novo pyrimidine synthesis pathway, effectively decreases proliferation of cancer cells via induction of replication and ribosomal stress in a p53- and checkpoint kinase 1 (Chk1)-dependent manner. Mechanistically, a block in replication and ribosomal biogenesis result in p53 activation paralleled by accumulation of replication forks that activate the ataxia telangiectasia and Rad3-related kinase/Chk1 pathway, both of which lead to cell cycle arrest. Since in the absence of functional p53 the cell cycle arrest fully depends on Chk1, combined DHODH/Chk1 inhibition in p53-dysfunctional cancer cells induces aberrant cell cycle re-entry and erroneous mitosis, resulting in massive cell death. Combined DHODH/Chk1 inhibition effectively suppresses p53-mutated tumors and their metastasis, and therefore presents a promising therapeutic strategy for p53-mutated cancers.
Insights
Inhibiting dihydroorotate dehydrogenase (DHODH) and checkpoint kinase 1 (Chk1) in p53-mutated cancers induces cell death. This combined therapy effectively suppresses tumor growth and metastasis, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- p53-mutated tumors display resistance to chemotherapy and increased metastasis.
- Dihydroorotate dehydrogenase (DHODH) is crucial for de novo pyrimidine synthesis.
Purpose of the Study:
- To investigate the therapeutic potential of DHODH inhibition in p53-mutated cancers.
- To elucidate the mechanisms underlying DHODH inhibition-induced cancer cell death.
Main Methods:
- Inhibition of DHODH and/or checkpoint kinase 1 (Chk1) in cancer cell lines and p53-mutated tumor models.
- Analysis of cell proliferation, cell cycle arrest, replication stress, and ribosomal biogenesis.
- Assessment of tumor suppression and metastasis in vivo.
Main Results:
- DHODH inhibition decreases cancer cell proliferation by inducing replication and ribosomal stress, dependent on p53 and Chk1.
- Combined DHODH and Chk1 inhibition leads to aberrant cell cycle re-entry and mitotic errors in p53-dysfunctional cells.
- This combination therapy effectively suppresses p53-mutated tumors and reduces metastasis.
Conclusions:
- Targeting DHODH, particularly in combination with Chk1 inhibition, is a promising strategy for treating p53-mutated cancers.
- The p53 and Chk1 pathways are critical mediators of the anti-cancer effects of DHODH inhibition.
More Related Videos
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Biosynthesis of Nucleic Acids
The DNA Replication Fork

